IOL CHEM AND PHARMA LTD

Manufactures active pharmaceutical ingredients (APIs) and industrial chemicals across two segments. The Pharmaceutical segment, which contributed 54.2% of FY26 segment revenue at ₹1,396.25 crore, makes Ibuprofen — where it is the largest global producer with 12,000 MTPA capacity — alongside a diversifying portfolio of non-Ibuprofen APIs such as Paracetamol, Metformin, Clopidogrel, Pantoprazole and Minoxidil, with the non-Ibuprofen share of pharma revenue rising from 18% in FY21 to 37% in FY26. The Chemical segment, 45.0% of segment revenue at ₹1,160.53 crore, produces Ethyl Acetate (1,20,000 MTPA), Acetic Anhydride (32,000 MTPA) and the newly commissioned Triacetin for backward integration, and was running at 98-100% capacity utilisation in Q4 FY26. Operations span 11 dedicated manufacturing units, with 14 USFDA DMFs and 21 EDQM CEPs in regulatory coverage, and products reach 80 countries. Q4 FY26 was the highest-ever quarter at ₹619 crore, lifting full-year revenue to ₹2,319.06 crore with EBITDA margin at 12.04%. Materials form the largest cost line at 64.8% of revenue, with employee cost at 10.7% and other opex at 13.6%.